<DOC>
	<DOCNO>NCT00832039</DOCNO>
	<brief_summary>Severe sepsis septic shock disease infectious origin high risk death . The purpose study determine whether intravenous application selenium ( give sodium-selenite ) reduce mortality patient severe sepsis septic shock . Additionally , investigate , whether measurement procalcitonin - marker infection - use guide anti-infectious measure disease .</brief_summary>
	<brief_title>Placebo Controlled Trial Sodium Selenite Procalcitonin Guided Antimicrobial Therapy Severe Sepsis</brief_title>
	<detailed_description>This multicenter trial German Network Sepsis ( SepNet ) patient severe sepsis septic shock . This study support unrestricted grant . The release reactive oxygen specie important factor development sepsis induce multiorgan dysfunction syndrome . Common protection mechanism impair syndrome . Serum level selenium , cofactor glutathionperoxidase , reduce . Several study suggest benefit selenium application patient severe sepsis data large clinical trial available . After inclusion study , patient randomly allocate placebo selenium group . Treating physician patient blind regard allocation . The selenium group receive sodium selenite intravenously - 1000 µg bolus follow continuous infusion 1000 µg per day end ICU treatment longer 21 day . Procalcitonin ( PCT ) biomarker elevate blood patient severe sepsis/septic shock . Data patient community acquire pneumonia demonstrate biomarker use decide duration antimicrobial therapy . Studies small sample size seem confirm ICU patient severe sepsis . However , need confirm large cohort . All patient randomly allocate PCT guide algorithm control group . In PCT-guided group , PCT measure randomization , day 4 , 7 , 10 , 14 . Depending PCT course , protocol recommends change , alter , stop anti-infectious measure . In control group , anti-infectious therapy leave discretion treat physician .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Selenious Acid</mesh_term>
	<mesh_term>Sodium Selenite</mesh_term>
	<criteria>Severe sepsis septic shock accord ACCP/SCCM criterion Onset severe sepsis septic shock &lt; 24 h Age &gt; = 18 year Informed consent Pregnant breastfeed woman Fertile female woman without effective contraception Participation interventional clinical trial within last 30 day Current participation study Former participation trial Selenium intoxication No commitment full patient support ( i.e . DNR order ) Patient 's death consider imminent due coexist disease Relationship patient study team member ( i.e . colleague , relative ) Infection guideline recommend long duration antimicrobial therapy ( i.e . endocarditis , tuberculosis , malaria etc ) Immunocompromised patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>sepsis</keyword>
	<keyword>adjunctive therapy</keyword>
	<keyword>sodium-selenite</keyword>
	<keyword>procalcitonin</keyword>
</DOC>